Cargando…
P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY
Autores principales: | Bachy, E., Savage, K. J., Huang, H., Kwong, Y. L., Gritti, G., Zhang, Q., Liberati, A. M., Cao, J., Yang, H., Hao, S., Hu, J., Zhou, K., Russo, F., Zhang, H., Sang, W., Ji, J., Ferreri, A. J. M., Damaj, G. L., Liu, H., Zhang, W., Ke, X., Ghiggi, C., Huang, S., Li, X., Yao, H., Paik, J., Novotny, W., Zhou, W., Zhu, H., Huang, J., Zinzani, P. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430666/ http://dx.doi.org/10.1097/01.HS9.0000847820.72232.2a |
Ejemplares similares
-
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
por: Bachy, Emmanuel, et al.
Publicado: (2023) -
P1240: ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
por: Zhang, L., et al.
Publicado: (2022) -
Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes
por: Tang, Y-T, et al.
Publicado: (2017) -
P1238: EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA
por: Yuan, X., et al.
Publicado: (2022) -
S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)